Advanced NanoTherapies Secures $31 Million in Latest Series B Funding Round

Advanced NanoTherapies secured $31 million in its latest Series B, adding another data point to the Healthcare & Life Sciences funding market.

Advanced NanoTherapies Raises $31 million in Funding

Advanced NanoTherapies is a Digital Health company focused on Deliver First-of-its-Kind Dual-Drug (Paclitaxel and Sirolimus) Nanoparticle-Coated Balloon Platform for Vascular Treatment.

Investors Behind the Funding

The round was backed by undisclosed investors. Funding Intelligence tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Advanced NanoTherapies operates in Healthcare & Life Sciences. Advanced NanoTherapies's Series B round shows investors are still backing digital health platforms with real scale narratives. At $31M, the deal suggests buyers want category leaders that can turn AI, automation, or workflow leverage into durable enterprise demand.

Strategic Use of Funds

Deliver First-of-its-Kind Dual-Drug (Paclitaxel and Sirolimus) Nanoparticle-Coated Balloon Platform for Vascular Treatment

Looking Ahead

Advanced NanoTherapies Secures Over $31M Series B to Deliver First-of-its-Kind Dual-Drug (Paclitaxel and Sirolimus) Nanoparticle-Coated Balloon Platform for Vascular Treatment

Source reference: original announcement/article.